HAHA, good article. Well you can't win them all. What the market is not taking into account is that $50m for Biota is pocket change compared to the market of LANI and the rest of the pipeline.
Sure Relenza and the legal action provides some cash flow, but the real upside to Biota will not come from either. LANI has the very real potential of becoming a monopoly stockpiling drug. For a multi-billion dollar stockpiling market and potentially larger seasonal market, LANI could make shareholders very very rich. The market has been defined by Tamiflu and Relenza, both having marketing problems early on. But the news has spread. Doctors nbow realise these types of drugs are out there and large Pharma are prepared to market them.
If Phase II LANI comes good then look out above!
Agree with the board that it's a pity BTA didn't get more, I still think GSK were at fault. If I was a director and the market cap for my stock was $130m and someone wanted to give me $130m cash.... well I would bloody well take it. It hurts, but it's a lesson. At least they tried.
BTA Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
